Ítem


COVID-19 in breast cancer patients: a subanalysis of the Oncovid registry

Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients. Methods: We report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population. Results: We included 495 breast cancer patients with a SARS-CoV-2 infection. Mean age was 62.6 years; 31.5% presented more than one comorbidity. The most frequent breast cancer subtype was luminal-like (n = 245, 49.5%) and 177 (35.8%) had metastatic disease. A total of 332 (67.1%) patients were receiving active treatment, with radical intent in 232 (47.6%) of them. Hospitalization rate was 58.2% and all-cause mortality rate was 20.3%. One hundred twenty-nine (26.1%) patients developed one COVID-19 complication, being acute respiratory failure the most common (n = 74, 15.0%). In the multivariable analysis, age older than 70 years, presence of COVID-19 complications, and metastatic disease were factors correlated with worse outcomes, while ongoing anticancer therapy at time of COVID-19 diagnosis appeared to be a protective factor. No particular oncological treatment was related to higher risk of complications. In the context of SARS-CoV-2 infection, 73 (18.3%) patients had some kind of modification on their oncologic treatment. At the first oncological reassessment (median time: 46.9 days ± 36.7), 255 (51.6%) patients reported to be fully recovered from the infection. There were 39 patients (7.9%) with long-term SARS-CoV-2-related complications. Conclusion: In the context of COVID-19, our data confirm that breast cancer patients appear to have lower complications and mortality rate than expected in other cancer populations. Most breast cancer patients can be safely treated for their neoplasm during SARS-CoV-2 pandemic. Oncological treatment has no impact on the risk of SARS-CoV-2 complications, and, especially in the curative setting, the treatment should be modified as little as possible

SAGE

Autor: Garrigós, Laia
Saura, Cristina
Martinez-Vila, Clara
Zambelli, Alberto
Bower, Mark
Pistilli, Barbara
Lambertini, Matteo
Ottaviani, Diego
Diamantis, Nikolaos
Lumsden, Ailsa
Pernas, Sonia
Generali, Daniele
Seguí, Elia
Viñas, Gemma
Felip, Eudald
Sanchez, Ana
Rizzo, Gianpiero
Santoro, Armando
Cortellini, Alessio
Perone, Ylenia
Chester, John
Iglesias, Maria
Betti, Marta
Vincenzi, Bruno
Libertini, Michela
Mazzoni, Francesca
Zoratto, Federica
Berardi, Rossana
Guida, Annalisa
Wuerstlein, Rachel
Loizidou, Angela
Sharkey, Rachel
Company, Juan Aguilar
Matas, Marta
Saggia, Chiara
Chiudinelli, Lorenzo
Colomba-Blameble, Emeline
Galazi, Myria
Mukherjee, Uma
Van Hemelrijck, Mieke
Marin, Mar
Strina, Carla
Prat, Aleix
Ciruelos, Eva Maria
Bertuzzi, Alexia
Mastro, Lucia del
Porzio, Giampiero
Newsom-Davis, Thomas
Ruiz, Isabel
Delany, Maria Belen
Krengli, Marco
Fotia, Vittoria
Viansone, Alessandro
Chopra, Neha
Romeo, Margarita
Salazar, Ramon
Pérez, Ignacio
Avanzo, Francesca d’
Franchi, Michela
Milani, Manuela
Pommeret, Fanny
Tucci, Marco
Pedrazzoli, Paolo
Harbeck, Nadia
Ferrante, Daniela
Pinato, David J.
Gennarion, Alessandra
Data: 2 novembre 2021
Resum: Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients. Methods: We report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population. Results: We included 495 breast cancer patients with a SARS-CoV-2 infection. Mean age was 62.6 years; 31.5% presented more than one comorbidity. The most frequent breast cancer subtype was luminal-like (n = 245, 49.5%) and 177 (35.8%) had metastatic disease. A total of 332 (67.1%) patients were receiving active treatment, with radical intent in 232 (47.6%) of them. Hospitalization rate was 58.2% and all-cause mortality rate was 20.3%. One hundred twenty-nine (26.1%) patients developed one COVID-19 complication, being acute respiratory failure the most common (n = 74, 15.0%). In the multivariable analysis, age older than 70 years, presence of COVID-19 complications, and metastatic disease were factors correlated with worse outcomes, while ongoing anticancer therapy at time of COVID-19 diagnosis appeared to be a protective factor. No particular oncological treatment was related to higher risk of complications. In the context of SARS-CoV-2 infection, 73 (18.3%) patients had some kind of modification on their oncologic treatment. At the first oncological reassessment (median time: 46.9 days ± 36.7), 255 (51.6%) patients reported to be fully recovered from the infection. There were 39 patients (7.9%) with long-term SARS-CoV-2-related complications. Conclusion: In the context of COVID-19, our data confirm that breast cancer patients appear to have lower complications and mortality rate than expected in other cancer populations. Most breast cancer patients can be safely treated for their neoplasm during SARS-CoV-2 pandemic. Oncological treatment has no impact on the risk of SARS-CoV-2 complications, and, especially in the curative setting, the treatment should be modified as little as possible
Format: application/pdf
Accés al document: http://hdl.handle.net/10256/21565
Llenguatge: eng
Editor: SAGE
Col·lecció: info:eu-repo/semantics/altIdentifier/doi/10.1177/17588359211053416
info:eu-repo/semantics/altIdentifier/issn/1758-8340
info:eu-repo/semantics/altIdentifier/eissn/1758-8359
Drets: Reconeixement-NoComercial 4.0 Internacional
URI Drets: http://creativecommons.org/licenses/by-nc/4.0
Títol: COVID-19 in breast cancer patients: a subanalysis of the Oncovid registry
Tipus: info:eu-repo/semantics/article
Repositori: DUGiDocs

Matèries

Autors